D228 is an orally active antiinflammatory agent. D228 reduces ConA induced T lymphocyte cell proliferation (IC50: 42.85 μM) and LPS induced B lymphocyte cell proliferation (IC50: 3.15 μM). D228 is effective against inflammatory bowel disease (IBD). D228 alleviates the DSS -induced inflammation response in the IBD model by downregulating the MyD88/TRAF6/p38 signaling [1].
References:
[1]. Tang ML, et al. From Hit to Lead: Discovery of First-In-Class Furanone Glycoside D228 Derived from Chimonanthus salicifolius for the Treatment of Inflammatory Bowel Disease. J Med Chem. 2024 Oct 10;67(19):17101-17123.
References:
[1]. Tang ML, et al. From Hit to Lead: Discovery of First-In-Class Furanone Glycoside D228 Derived from Chimonanthus salicifolius for the Treatment of Inflammatory Bowel Disease. J Med Chem. 2024 Oct 10;67(19):17101-17123.